Holen Sie sich die Stockscreener-App
6.20
1.14%
0.07
Handel nachbörslich:
6.30
0.10
+1.61%
Schlusskurs vom Vortag:
$6.13
Offen:
$6.14
24-Stunden-Volumen:
38,667
Relative Volume:
0.68
Marktkapitalisierung:
$103.69M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.88M
KGV:
-6.3265
EPS:
-0.98
Netto-Cashflow:
$-10.29M
1W Leistung:
-3.13%
1M Leistung:
+1.14%
6M Leistung:
-9.36%
1J Leistung:
+20.62%
1-Tages-Spanne:
$5.95
$6.25
1-Wochen-Bereich:
$5.87
$6.50
52-Wochen-Spanne:
$4.65
$10.24
Coya Therapeutics Inc Stock (COYA) Company Profile
Firmenname
Coya Therapeutics Inc
Sektor
Branche
Telefon
650.739.3939
Adresse
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Vergleichen Sie COYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
6.20 | 102.52M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Lake Street | Buy |
| 2024-12-04 | Eingeleitet | D. Boral Capital | Buy |
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update - BioSpace
Coya Therapeutics 2025 Q2 Earnings Sharp Loss Widens, Revenue Collapses - AInvest
Coya Therapeutics Reports Increased Losses Amid Development Focus - TipRanks
Coya Therapeutics, Inc. (COYA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Coya Therapeutics' $75M Mixed Shelf: Fueling Neuroinflammation Breakthroughs in ALS, Alzheimer's, and Dementia - AInvest
Coya Therapeutics Files $75 Million Mixed Shelf - MarketScreener
Coya Therapeutics reports Q2 EPS (36c), consensus (43c) - TipRanks
Coya Therapeutics Highlights Q2 2025 Financial Results - TipRanks
Coya Therapeutics, Inc. SEC 10-Q Report - TradingView
Is Coya Therapeutics Inc. trending in predictive chart modelsDay Trading Setup and Momentum Analysis - Newser
Using Python tools to backtest Coya Therapeutics Inc. strategiesReal-Time AI Generated Market Forecast - Newser
Sector ETF performance correlation with Coya Therapeutics Inc.Trading Watchlist with Real Time Filters - Newser
Tools to monitor Coya Therapeutics Inc. recovery probabilityConservative Equity Setup with Signal Analysis - Newser
Published on: 2025-08-11 07:24:51 - Newser
Coya Therapeutics Inc. recovery potential after sell offBuy Strategy with Smart Exit Timing - Newser
Understanding Coya Therapeutics Inc.’s price movementConservative Asset Allocation Risk Analysis - Newser
Intrinsic Value of Coya Therapeutics Inc. Stock: Is It Undervalued or OvervaluedAI Volatility Forecast and Risk Monitor - Newser
Coya Therapeutics COYA Q2 2025 Earnings Preview Upside Potential on Promising Product Pipeline - AInvest
How Resilient Is Coya Therapeutics Inc. Stock During Economic DownturnsFree Step-by-Step Stock Investment Guide - Newser
How Coya Therapeutics Inc. stock performs during market volatilityTrade Plan With Low Risk High Return - Newser
What drives Coya Therapeutics Inc. stock priceLightning-fast capital gains - Jammu Links News
Does Coya Therapeutics Inc. stock perform well during market downturnsTrack top-performing stocks in real-time - Jammu Links News
How does Coya Therapeutics Inc. generate profit in a changing economyFree Trend-Following Techniques - Jammu Links News
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains? - MSN
Is it the right time to buy Coya Therapeutics Inc. stockGet daily updates on top-performing stocks - Jammu Links News
How many analysts rate Coya Therapeutics Inc. as a “Buy”Explosive earnings growth - Jammu Links News
How strong is Coya Therapeutics Inc. company’s balance sheetUnlock powerful portfolio optimization tools - Jammu Links News
What catalysts could drive Coya Therapeutics Inc. stock higher in 2025Overwhelming financial success - Jammu Links News
What institutional investors are buying Coya Therapeutics Inc. stockAchieve breakthrough results with expert guidance - Jammu Links News
Is Coya Therapeutics Inc. a growth stock or a value stockTremendous growth opportunities - Jammu Links News
What are the technical indicators suggesting about Coya Therapeutics Inc.Get insider insights into market trends - Jammu Links News
What are Coya Therapeutics Inc. company’s key revenue driversCapitalize on emerging trends for profits - Jammu Links News
Is Coya Therapeutics Inc. stock ready for a breakoutReal Market Tracker with Price Action Tools - Newser
Should you wait for a breakout in Coya Therapeutics Inc.Free Top Gaining Picks With Entry Signals - Newser
Why Coya Therapeutics Inc. stock attracts strong analyst attentionTrade Safety Matrix for Conservative Traders - Newser
How to manage a losing position in Coya Therapeutics Inc.Intraday Strategy with Real Time Monitoring - Newser
Applying Wyckoff theory to Coya Therapeutics Inc. stockFree AI Screening for Swing Trade Picks - Newser
Is Coya Therapeutics Inc. stock overvalued or undervaluedTop Growth Forecasts Backed By Experts - Jammu Links News
Price action breakdown for Coya Therapeutics Inc.Free Fundamental Winners With Safe Entry Plan - Newser
Published on: 2025-07-31 11:13:46 - metal.it
Published on: 2025-07-30 21:39:20 - Newser
Merck to discontinue drug from Pandion deal; Coya’s IND for ALS drug is delayed - Endpoints News
Finanzdaten der Coya Therapeutics Inc-Aktie (COYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):